AVODART® Alopecia Post-marketing Surveillance (PMS) (AVODART®PMS)

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Alopecia

Treatments: Drug: Dutasteride

Study type: Observational

Funder types: Industry

Identifiers

NCT01004809

113797

Details and patient eligibility

About

Post-marketing surveillance(PMS) to monitor the safety and effectiveness of dutasteride in Korean androgenetic alopecia patients

Full description

An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and effectiveness of dutasteride administered in Korean androgenetic alopecia patients according to the prescribing information

Enrollment: 712 patients

Sex: Male

Ages: 18 to 41 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men (18-41 years of age) with male pattern hair loss (androgenetic alopecia)
• Subjects with no experience of treatment using dutasteride
• Subjects who the investigator believes that they can and will comply with the requirements of the protocol
• Subjects who prescribed with dutasteride according to the Prescribing Information

Exclusion criteria

• Considering the nature of observational study, GSK Korea encourages the doctors participating in this study to enrol the subjects prescribed with dutasteride following the locally approved Prescribing Information. Subject who give informed consent is enrolled. However, if institution waives the requirement for informed consent, informed consent is not required. In this case, monitoring does not proceed.

Trial design

712 participants in 1 patient group

Dutasteride

Description:

Patients administrated dutasteride with male hair loss

Treatment:

Drug: Dutasteride